<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="28675">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02733432</url>
  </required_header>
  <id_info>
    <org_study_id>CD101.TP.2.01</org_study_id>
    <nct_id>NCT02733432</nct_id>
  </id_info>
  <brief_title>RADIANT: CD101 vs Standard of Care in Subjects With Acute Vaginal Yeast Infections</brief_title>
  <official_title>A Phase 2, Multicenter, Randomized, Active-controlled Study of the Safety and Tolerability of Two Formulations of CD101 Compared to Fluconazole for the Treatment of Moderate to Severe Episodes of Acute Vulvovaginal Candidiasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cidara Therapeutics Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cidara Therapeutics Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if two topical formulations of CD101 are safe and
      effective in the treatment of acute moderate to severe vulvovaginal candidiasis (VVC)
      compared to oral fluconazole.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 2, multicenter, randomized, open-label, sponsor-blind, active-controlled,
      dose-ranging trial of female subjects with an acute moderate to severe episode of
      vulvovaginal candidiasis. Subjects will be randomized to 1 of 3 treatment arms; CD101 gel,
      CD101 ointment, or oral fluconazole. After randomization, subjects will be seen on Day 7
      (+/-2 days), Day 14 (+/- 2 days), &amp; Day 28 (+/-7 days) to assess therapeutic cure and
      safety.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2016</start_date>
  <completion_date type="Actual">February 2017</completion_date>
  <primary_completion_date type="Actual">December 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Subjects with Incidence of Treatment Emergent Adverse Events [Safety and Tolerability]</measure>
    <time_frame>Day 28 - 35</time_frame>
    <description>adverse events, clinical chemistry and hematology, pelvic exams</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Vulvovaginal Scoring System</measure>
    <time_frame>Day 7 (+/- 2days)</time_frame>
    <description>Change in clinical signs and subject symptoms of VVC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Vulvovaginal Scoring System</measure>
    <time_frame>Day 14 (+/- 2days)</time_frame>
    <description>Change in clinical signs and subject symptoms of VVC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Vulvovaginal Scoring System</measure>
    <time_frame>Day 28 - 35</time_frame>
    <description>Change in clinical signs and subject symptoms of VVC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mycological Culture</measure>
    <time_frame>Day 7 (+/- 2days)</time_frame>
    <description>Culture negative for Candida</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mycological Culture</measure>
    <time_frame>Day 14 (+/- 2days)</time_frame>
    <description>Culture negative Candida</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mycological Culture</measure>
    <time_frame>Day 28 -35</time_frame>
    <description>Culture negative Candida</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">125</enrollment>
  <condition>Candidiasis, Vulvovaginal</condition>
  <condition>Mycoses</condition>
  <condition>Yeast Infection</condition>
  <condition>Moniliasis, Vulvovaginal</condition>
  <condition>Vaginitis, Monilial</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CD101 gel for external and intravaginal application</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CD101 ointment for external and intravaginal application</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>oral fluconazole</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CD101 gel (3%)</intervention_name>
    <description>intravaginally applied topical gel on Days 1 and 2</description>
    <arm_group_label>Cohort 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CD101 gel (1%)</intervention_name>
    <description>externally applied topical gel twice daily up to 3 days as needed</description>
    <arm_group_label>Cohort 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CD101 ointment (6%)</intervention_name>
    <description>intravaginally applied topical ointment on Day 1</description>
    <arm_group_label>Cohort 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CD101 ointment (1%)</intervention_name>
    <description>externally applied ointment twice daily up to 3 days as needed</description>
    <arm_group_label>Cohort 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluconazole</intervention_name>
    <description>oral fluconazole (150mg) on Day 1</description>
    <arm_group_label>Cohort 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  moderate to severe acute vulvovaginal candidiasis (severity score &gt;7)

          -  positive K-OH wet preparation for pseudohyphae or budding yeast or positive BD Affirm
             test or positive vaginal culture for Candida species

          -  vaginal pH &lt;4.5 for subjects with positive K-OH wet preparation

          -  able to give written informed consent

        Exclusion Criteria:

          -  receipt of intravaginal or systemic antifungal therapy within 7 days of randomization

          -  known or suspected infectious causes of vulvovaginitis other than candidisasis

          -  history of genital herpes

          -  planned treatment or surgery during the study period for cervical intraepithelial
             neoplasia or cervical carcinoma

          -  need for non-protocol systemic or vaginal antifungal therapy

          -  history of hypersensitivity or allergic reaction to echinocandins, azoles, or their
             excipients

          -  pregnant females

          -  females who are breast feeding

          -  women intending to become pregnant during the study period

          -  recent use of an investigational medicinal product within 28 days or presence of an
             investigational device at the time of screening

          -  subjects who use or anticipate use of intravaginal products

          -  have any condition that the Investigator believes would put the subject at risk for
             participation or would confound the results of the study
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alena Jandourek, MD</last_name>
    <role>Study Director</role>
    <affiliation>Cidara Therapeutics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama at Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Precision Trials AZ</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Women's Clinical, P.A.</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Women's Health Care Research Corp</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Olympian Clinical Research</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Women's Medical Research</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33759</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altus Research Inc</name>
      <address>
        <city>Lake Worth</city>
        <state>Florida</state>
        <zip>33461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New Age Medical Research Corporation</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33186</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Augusta University</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30912</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trials Management LLC</name>
      <address>
        <city>Metairie</city>
        <state>Louisiana</state>
        <zip>70006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wayne State University</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saginaw Valley Medical Research Group LLC</name>
      <address>
        <city>Saginaw</city>
        <state>Michigan</state>
        <zip>48604</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alliance Women's Research Group LLC</name>
      <address>
        <city>Delran</city>
        <state>New Jersey</state>
        <zip>08075</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lawrence OB GYN Clinical Research LLC</name>
      <address>
        <city>Lawrenceville</city>
        <state>New Jersey</state>
        <zip>08648</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Soffolk OB/GYN</name>
      <address>
        <city>Port Jefferson</city>
        <state>New York</state>
        <zip>11777</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eastern Carolina Women's Center</name>
      <address>
        <city>New Bern</city>
        <state>North Carolina</state>
        <zip>28562</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hawthorne Medical Research Inc</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Unified Women's Clinical Research - Hickory</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Women's Health Research</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Drexel University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>TMC Life Research Inc.</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77054</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trials of Texas Inc</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tidwewater Physicians for Women</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seattle Women's Health, Research, Gynecology</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2017</verification_date>
  <lastchanged_date>February 27, 2017</lastchanged_date>
  <firstreceived_date>March 28, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Mycoses</mesh_term>
    <mesh_term>Candidiasis</mesh_term>
    <mesh_term>Vaginitis</mesh_term>
    <mesh_term>Candidiasis, Vulvovaginal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Fluconazole</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
